- ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
- PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
- Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
- ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
- ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
- ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
- ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
- ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
More ▼
Key statistics
On Friday, Resmed Inc (RMD:ASX) closed at 28.52, -16.78% below its 52-week high of 34.27, set on Aug 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.40 |
---|---|
High | 28.62 |
Low | 28.31 |
Bid | 28.51 |
Offer | 28.65 |
Previous close | 28.43 |
Average volume | 2.86m |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 0.2967 AUD |
---|---|
Annual div yield (ADY) | 1.04% |
Div ex-date | May 08 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 20 minutes, as of Jul 05 2024 07:10 BST.
More ▼